home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  June 19, 2021
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [7] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 496 active entries

LIONEX Diagnostics & Therapeutics GmbH

Salzdahlumer Str. 196
Braunschweig, 38126

Phone: 0049 531 260 12 66
Fax: 0049 531 260 11 59

Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Lionex is a growing biotech company dedicated to modern biomedicine for human health. Lionex is developing protein-focused technologies to enable the accelerated identification, development and production of new and improved products (diagnostics, drugs and vaccines)  for combating major diseases, e.g. tuberculosis/HIV, heart diseases and cancer. Products: -Development of specific and rapid Tuberculosis diagnostic kits.
-Several serological kits (IgG,-A and -M) for Tuberculosis diagnosis have been developed showing high sensitivities and specifcities for pulmonary and extra-pulmonary TB. 

LIONEX  TB-ST+2, a second generation TB rapid tests for use with serum and blood has been launched. It provids results in 15 minutes and shows high specificity (99%) and high sensitivity (65%), specially in smear negative active TB.

-LIONEX continues to increase its panel of high quality mycobacterial antigens. The recombinant antigens are being used to develop test for sero-diagnosis of TB. Special attention is being given to cost-effective and rapid tests.

-In addition, based on proprietary methods rapid molecular tests have been developed for differentiating tuberculous bacteria from the nontuberculous ones.

-A rapid 3 hour test for differentiating M. tuberculosis from M. bovis has been developed.

Cancer: Lx-Bladder a cancer therapeutic is entering clincial trial inn humans.

Contract manufacturing: Large quantities of recombinant antigens, DNA, LAM

Selected Categories:
Product Company   Service Company
- Research
- Immunoassay
- in vitro
- Medical
- Research
- Production
- Research

Last update of this entry: June 15, 2016

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.